The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
A roundup of the latest market developments from the pipelines of the pharmaceutical majors, featuring news from Roche.
Editor's Note: This article was updated on a continuous basis for news announced from Wednesday, April 11, 2017 to Tuesday,...
Novartis plans to invest more than $100 million to advance research and development (R&D) of treatments for malaria.
The company also plans to implement an equitable pricing strategy to maximize patient access in malaria-endemic countries when...
Genentech, a Roche company, has signed an option and license agreement with Kineta Chronic Pain, a subsidiary of Kineta, a biopharmaceutical company, to develop Kineta's α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists for treating...
Sanofi and Advent International, a Boston-based private-equity firm, have entered into negotiations under which Advent would acquire Zentiva, Sanofi’s European generics business for EUR 1.9 billion ($2.4 billion).
Advent will work with Sanofi to...
The US Food and Drug Administration (FDA) has finalized a guidance, Special Protocol Assessment Guidance for Industry, which provides drug manufacturers with information about the procedures and policies adopted by the FDA’s Center for Drug...
The European Medicines Agency (EMA) has reallocated the medicines for the UK’s portfolio of centrally authorized products in anticipation of Brexit, the UK’s withdrawal from the European Union (EU). Over 370 centrally authorized products have been...
Boehringer Ingelheim (BI) and Eli Lilly and Company have partnered in an academic collaboration with the University of Oxford to investigate the effects of the companies’ diabetes drug, Jardiance (empagliflozin), on the progression of kidney...
GlaxoSmithKline (GSK) has agreed to transfer its portfolio of approved and investigational rare-disease gene therapies to Orchard Therapeutics, a Foster City, California-based clinical-stage biotechnology company.
Under the agreement, GSK will...
Shire has agreed to sell its oncology business to Servier, a Suresnes, France-based pharmaceutical company, for $2.4 billion.
Shire’s oncology business includes in-market products, Oncaspar (pegaspargase), a component of a multi-agent treatment...
A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Bristol-Myers Squibb and Novartis.
Editor's Note: This article was updated on a continuous basis for news announced from Wednesday April...
Bristol-Myers Squibb (BMS) and Illumina, a San Diego, California-headquartered company developing and commercializing systems for analysis of genetic variation and function, have partnered to use Illumina’s sequencing technology to develop and...
Sanofi is investing EUR 350 million ($431 million) for the construction of a new vaccine-manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario.
The new facility will allow Sanofi Pasteur, the global vaccines...
Pfizer has decided to relocate its New York City headquarters to a new building in the city. The company signed a 20-year lease for The Spiral, an office tower being built at Hudson Yards of Manhattan.
As part of its 20-year lease agreement,...
Amgen plans to build a new biomanufacturing plant at its campus in West Greenwich, Rhode Island. In January 2018, Amgen announced a five-year capital investment plan of $3.5 billion, which included committing up to $300-million to build a new...
Alexion Pharmaceuticals, a New Haven, Connecticut-based pharmaceutical company, has agreed to acquire Wilson Therapeutics, a Stockholm, Sweden-headquartered biopharmaceutical company that develops therapies for patients with rare copper-mediated...
